Decision Support Tool Identifies Ulcerative Colitis Patients Most Likely to Achieve Remission With Vedolizumab vs Adalimumab

Abstract Background & Aims We have previously validated a clinical decision support tool (CDST) (vedolizumab CDST [VDZ-CDST]) for clinical and endoscopic remission with VDZ in ulcerative colitis (UC). We aim to expand the validation for predicting histoendoscopic mucosal improvement (HEMI) with...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Inflammatory bowel diseases 2022-10, Vol.28 (10), p.1555-1564
Hauptverfasser:	Dulai, Parambir S, Wong, Emily C L, Reinisch, Walter, Colombel, Jean-Frederic, Marshall, John K, Narula, Neeraj
Format:	Artikel
Sprache:	eng
Schlagworte:	Adalimumab - therapeutic use Antibodies, Monoclonal, Humanized - therapeutic use Clinical Research Colitis, Ulcerative - chemically induced Colitis, Ulcerative - drug therapy Gastrointestinal Agents - therapeutic use Humans Remission Induction Retrospective Studies Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Abstract Background & Aims We have previously validated a clinical decision support tool (CDST) (vedolizumab CDST [VDZ-CDST]) for clinical and endoscopic remission with VDZ in ulcerative colitis (UC). We aim to expand the validation for predicting histoendoscopic mucosal improvement (HEMI) with VDZ vs adalimumab (ADA). Methods In a post hoc analysis of a clinical trial for VDZ vs ADA in moderate to severe UC (VARSITY trial; NCT02497469), comparative accuracy was evaluated for the VDZ-CDST among an external validation cohort of VDZ- and ADA-treated patients for week 52 HEMI (Mayo endoscopic subscore 0-1 and Geboes score
ISSN:	1078-0998 1536-4844
DOI:	10.1093/ibd/izab310